Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.4000 |
Strike | 2.50 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 90 |
Discover how BioCardia Inc navigates clinical advancements and financial efficiencies in the first quarter of 2024.
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlight
Key Insights BioCardia to hold its Annual General Meeting on 20th of May Salary of US$515.5k is part of CEO Peter...